Pharmaceuticals

Global Non Small-Cell Lung Cancer Market (Type, Therapy and Geography) - Size, Share, Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2020

  • ALL242559
  • 0 Pages
  • November 1999
  • Pharmaceuticals

Non-small cell Lung cancer is the malignant tissue formation in the lung, usually in the cell lining air passage, which is characterized by abnormal cell growth in lung tissue. Globally, lung cancer is one of the leading causes of death since the past several decades. According to the American lung association, the number of deaths due to lung cancer has increased ~3.5% from ~152,156 cases in 1999 to ~157,499 in 2012. Furthermore, it is estimated that 158,040 Americans are would die due to lung cancer by 2015. According to the American Society of cancer, non small-cell lung cancer accounts for ~85% to 90% of overall lung cancer cases and the trend is expected to grow with the same momentum. Thus, a large patient base of non small-cell lung cancer depicts the unmet need for diagnosis and treatment. It has been observed that non small-cell lung cancer is the most prevalent type of lung cancer commonly caused due to active and passive smoking. 

Conventionally, the treatment pattern for non-small cell lung cancer is focussed around chemotherapy. Surgery is not suitable for most of the people diagnosed with lung cancer, thus, chemotherapy remains the cornerstone for non-small cell lung cancer treatment. However, emergence of targeted therapies for patients has widened the scope of NSCLC treatment by providing lesser side effects and effective treatments as compared to chemotherapy. The launch of new drugs in several new drugs classes would address the potential unmet need among NSCLC patients over the forecast period. The potential drivers for lung cancer therapeutic market include active & passive tobacco smoking, geriatric population and improper lifestyle. However, the availability of generic drugs, limited treatment options and unmet need of diagnosis might hamper the market. Chemotherapy and radiation therapy poses a bigger challenge in terms of adverse effects arising from treatment. Thus, key players have shifted their focus towards innovative therapies and safer therapeutics. For example, on April 20, 2015, global strategic partner Pfizer and Merck initiated the phase III study for Avelumb, to assess its safety and efficacy as compared to docetaxel in the patients with non-small cell lung cancer. 

Global non small-cell lung cancer market is segmented into types, therapeutics and geography. Based on the types, global non small-cell lung cancer market is further segmented into squamous cell carcinoma, adenocarcinoma, large cell carcinoma and others. The market is segmented on the basis of therapeutics into chemotherapy, targeted therapy, surgery, radiotherapy and pipeline drugs. Furthermore, the market is segmented, on the basis of geography, across North America, Europe, Asia-Pacific and LAMEA. Key players profiled in the market are Pfizer, Roche, AstraZeneca, Eli Lily, GlaxoSmithKline, Novartis AG, Merck & Co., and Agennix AG. Collaboration, product launch and acquisition are some of the strategies adopted by key players in the non-small cell lung cancer market. For example, on April 21, 2015, Pfizer received the USFDA approval for potential treatment of patients with ROS1-positive non-small cell lung cancer. On November 21, 2014, GSK collaborated with Clovis oncology to design clinical trials for the evaluation of new combination therapy used in NSCLC treatments. 

KEY MARKET BENEFITS

  • The report provides a quantitative analysis of the current market and estimations through 2014‐2020 that help identify the prevailing market opportunities 

  • Non small cell lung cancer market conditions are comprehensively analyzed based on region 

  • Key market players within the non small cell lung cancer market are profiled in the report and their strategies are analyzed thoroughly, which helps in understanding the competitive outlook of the market 

  • Extensive analysis of the market is conducted by closely following key product positioning and monitoring the top contenders within the market framework

  • Comprehensive analysis of factors that drive and restrict the growth of the global non-small cell lung cancer market, is provided in the report

  • Exhaustive analysis of the global non-small cell lung cancer devices market by therapeutics type helps in understanding the types of therapeutics that are currently being used along with the variants that would gain prominence in future

KEY MARKET SEGMENTS

Global non small-cell lung cancer market is segmented as below:

  • Global non small-cell lung cancer market- by Type

    • Squamous cell (epidermoid) carcinoma

    • Adenocarcinoma

    • Large cell (undifferentiated) carcinoma

    • Other

  • Global non small-cell lung cancer market- by Therapy

    • Chemotherapy

    • Targeted therapy

    • Surgery

    • Radiotherapy

    • Laser therapy 

    • Photodynamic therapy (PDT)

    • Others

  • Global non small-cell lung cancer market- by Geography

    • North America

    • Europe

    • Asia-Pacific

    • LAMEA

Please Select Format

Enquiry About Report

Need More Information

Contact us
+ 1-800-910-6452
+1-971-202-1575
+91 20 66346066
--- or ---
help@bigmarketresearch.com

 

UPCOMING MARKET RESEARCH REPORTS

Global General Medicine Education Publishing Market (Type, Geography) Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, Forecast (2013-2020)

General medicine is a branch of medicine that deals with diagnosis and treatment of diseases associated with internal organs. It is also called as Internal Medicine. General medicine education market has shown substantial growth due to the adoption of internal medicine as a career option by medical students.

July 2017  |   Price:$ 5370    | Pre Book Price:$ 5370

Read More >>

Cancer Vaccine Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Cancer vaccines are biological response modifiers. These vaccines work by stimulating or restoring the immune system’s ability to fight against infections and diseases. It is used either as stand-alone therapies ...

March 2017  |   Price:$ 7695    | Pre Book Price:$ 7695

Read More >>

Radiopharmaceuticals Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Radiopharmaceutical is a radioactive pharmaceutical agent which is used diagnostic or therapeutic procedures. A radiopharmaceutical is made up of two components that are drug component and radioactive component. This radioactive ...

March 2017  |   Price:$ 7695    | Pre Book Price:$ 7695

Read More >>

Pharmaceutical Excipients Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Pharmaceutical excipients are substances other than the pharmacologically active drug or prodrug which are included in the manufacturing process or are contained in a finished pharmaceutical product dosage form. The ...

March 2017  |   Price:$ 7695    | Pre Book Price:$ 7695

Read More >>

Over the Counter (OTC) & Diet Supplementary Market Global Scenario, Market Size, Outlook, Trend and Forecast, 2015- 2024

Over the counter (OTC) drugs are those drugs which can be picked by consumer without the prescription of doctors intended to use for diagnosis, cure, mitigation, treatment or prevention of ...

March 2017  |   Price:$ 7695    | Pre Book Price:$ 7695

Read More >>

World Active Pharmaceutical Ingredient (API) Market - Opportunities and Forecasts, 2014 - 2020

Increase in Abbreviated New Drug Applications (ANDA) over the past years has fostered the demand for API market. Furthermore, Indian companies making increased entries related to Drug Master File (DMF) ...

July 2017  |   Price:$ 5370    | Pre Book Price:$ 5370

Read More >>

2017 © Copyright Big Market Research

View Pricing >>